Join our 20th anniversary celebrations by browsing through the journal’s milestone achievements and our specially commissioned Editorial collection.
Articles
-
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects
-
Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs
-
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
-
Progressive structural bone changes and their relationship with treatment in patients with psoriatic arthritis: a longitudinal HR-pQCT study
-
Use of NSAIDs in treating patients with arthritis
-
Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes
-
Complement and systemic lupus erythematosus
-
Liver involvement in subjects with rheumatic disease
-
Remission in psoriatic arthritis: is it possible and how can it be predicted?
Reflections of a rheumatologist
Editors-in-Chief
Professor Christopher Buckley, University of Birmingham and University of Oxford, UK
Professor Harris Perlman, Northwestern University, USA
Trending articles
Click here to view which articles have been shared the most in the last month.
First Author Profiles
Meet this month's featured authors!
Aims and scope
Established in 1999, Arthritis Research and Therapy is an international, open access, peer-reviewed journal, publishing original articles in the area of musculoskeletal research and therapy as well as, reviews, commentaries and reports.
A major focus of the journal is on the immunologic processes leading to inflammation, damage and repair as they relate to autoimmune rheumatic and musculoskeletal conditions, and which inform the translation of this knowledge into advances in clinical care.
Original basic, translational and clinical research is considered for publication along with results of early and late phase therapeutic trials, especially as they pertain to the underpinning science that informs clinical observations in interventional studies.
A major focus of the journal is on the immunologic processes leading to inflammation, damage and repair as they relate to autoimmune rheumatic and musculoskeletal conditions, and which inform the translation of this knowledge into advances in clinical care.
Original basic, translational and clinical research is considered for publication along with results of early and late phase therapeutic trials, especially as they pertain to the underpinning science that informs clinical observations in interventional studies.
Prognostic factors for progression of osteoarthritis of the hip: a systematic review
The hip is the third joint most commonly affected by osteoarthritis (OA) and with no therapeutic cure for hip OA, predicting which patients with hip OA are more likely to show disease progression is important for healthcare professionals.
In this systematic review, Teirlinck et al assess the existing evidence of patient, health, and diagnostic variables associated with the progression in patients with hip osteoarthritis.
Advertisement
Follow
Annual Journal Metrics
-
Speed
56 days to first decision for reviewed manuscripts only
48 days to first decision for all manuscripts
121 days from submission to acceptance
33 days from acceptance to publicationCitation Impact
4.148 - 2-year Impact Factor
4.768 - 5-year Impact Factor
1.347 - Source Normalized Impact per Paper (SNIP)
2.094 - SCImago Journal Rank (SJR)Usage
1,823,999 Downloads
1,140 Altmetric Mentions
Advertisement
